Welcome to the UPF Digital Repository

Novel oral mTORC1/2 inhibitor TAK-228 has synergistic antitumor effects when combined with paclitaxel or PI3Kα inhibitor TAK-117 in preclinical bladder cancer models



Novel oral mTORC1/2 inhibitor TAK-228 has synergistic antitumor effects when combined with paclitaxel or PI3Kα inhibitor TAK-117 in preclinical bladder cancer models

Thumbnail
Document Type: Article
Version: Accepted version
Date: 2019

This item appears in the following Collection(s)

Search DSpace


Advanced Search

Browse

My Account

Statistics

Compliant to Partaking